Lewy Body Dementia Pathophysiology and Cognitive Decline

Lewy body dementia is an umbrella term encompassing dementia with Lewy bodies and Parkinson’s disease dementia, both characterised by the abnormal aggregation of α-synuclein into Lewy bodies. These proteinaceous inclusions disseminate through brainstem, limbic and cortical regions in a heterogeneous manner, leading to multifocal neurodegeneration. The progressive accumulation of α-synuclein often interacts with Alzheimer-type pathologies such as β-amyloid plaques and tau tangles, exacerbating synaptic dysfunction and neuronal loss. Neurotransmitter deficits—most notably in the cholinergic and dopaminergic systems—underlie fluctuating attention, executive dysfunction and visuospatial impairments that differentiate this condition from other dementias. Advanced imaging and fluid biomarkers, including measures of neurofilament light chain and functional connectivity, now enable in vivo characterisation of disease stages and trajectories. A deeper understanding of these pathophysiological processes is essential for the development of targeted therapeutics and for improving early diagnosis and patient management worldwide.

Research from Nature Portfolio

Recent studies have used large autopsy cohorts combined with natural language processing to map clinical trajectories across neurodegenerative disorders, revealing distinct prodromal signs that may distinguish Lewy body dementia from other syndromes. By analysing thousands of clinical records, researchers have begun to identify patterns of early cognitive and motor features that predict underlying pathology and subtypes. Another line of work has applied data-driven disease progression models to post-mortem α-synuclein density scores, uncovering at least three distinct temporal trajectories of Lewy pathology. Some patients exhibit earliest involvement in the olfactory bulb progressing to limbic structures, while others show an initial brainstem-centred spread. These heterogenous patterns correlate with differences in cognitive decline, motor impairment and co-existing Alzheimer-type changes.

Lewy Body Dementia Pathophysiology and Cognitive Decline publication trend

The graph below shows the total number of articles in lewy body dementia pathophysiology and cognitive decline across all publications each year (not limited to Nature Index journals).

Technical terms

Lewy body: intracellular aggregates of misfolded α-synuclein protein characteristic of Lewy body dementia.

α-Synuclein: neuronal protein prone to misfolding that forms fibrillar aggregates in Lewy body disorders.

Neurofilament light chain (NfL): structural axonal protein released during neurodegeneration and measurable in tissue and biofluids.

Clinical mild cognitive impairment (MCI): early stage cognitive decline that does not meet criteria for dementia but often precedes it.

Functional connectivity: coordinated activity among brain regions as measured by neuroimaging techniques.

References

1. Identification of clinical disease trajectories in neurodegenerative disorders with natural language processing. Nature Medicine (2024).
2. Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology. Nature Communications (2024).
3. Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson’s disease dementia. Translational Neurodegeneration (2023).
4. Enhanced Spine Stability and Survival Lead to Increases in Dendritic Spine Density as an Early Response to Local Alpha-Synuclein Overexpression in Mouse Prefrontal Cortex. Cellular and Molecular Neurobiology (2024).